

# Typhoid Vaccine

Revision Date: February 10, 2015

Please consult the Product Monograph <sup>1</sup> for further information about the vaccine.		
	<b>TYPHERIX®</b>	<b>TYPHIM Vi®</b>
<b>Manufacturer</b>	GlaxoSmithKline Inc.	Sanofi Pasteur SA distributed by Sanofi Pasteur Limited
<b>Licensed use</b>	Individuals two years of age and older. <sup>1</sup>	
<b>Off-license use</b>	None	
<b>Indications for use of provincially funded vaccine</b>	<b>Individuals two years of age and older who are:</b> <ul style="list-style-type: none"> <li>Household or intimate contacts of a typhoid carrier. Refer to the most recent version of the <i>Public Health Notifiable Disease Management Guidelines – Typhoid</i>.<sup>3</sup></li> <li>Laboratory workers who regularly manipulate the <i>Salmonella typhi</i> organism.</li> </ul>	
<b>Dose</b>	0.5 mL	
<b>Route</b>	Intramuscular injection	
<b>Schedule</b>	<b>Two years of age and older:</b> <ul style="list-style-type: none"> <li>❖ One dose</li> <li>❖ Reinforcing dose – every three years for individuals at continued risk.<sup>2</sup> See Indications for use of provincially funded vaccine (above).</li> </ul>	
<b>Contraindications</b>	<ul style="list-style-type: none"> <li>Known severe hypersensitivity to any of the components of the vaccine or its container.</li> <li>Anaphylaxis or other severe allergic reaction to a previous dose of vaccine containing typhoid antigen.</li> </ul>	
<b>Precautions</b>	Typhoid vaccines does not protect against will not provide protection against species of <i>Salmonella</i> other than <i>S.typhi</i> . <sup>1</sup>	
<b>Possible reactions</b>	See Product Monograph	
<b>Pregnancy</b>	No information is available on the safety in pregnancy; however, there is not theoretical reason to suspect an increased risk from inactivated vaccines. <sup>2</sup> Typhoid vaccine should be considered for pregnant women when indicated. <sup>2</sup>	
<b>Lactation</b>	Although there are no data, it is reasonable to assume that inactivated typhoid vaccine could be used safely in breastfeeding mothers. <sup>2</sup>	

## Typhoid Vaccine

## References

- <sup>1</sup> GlaxoSmithKline Inc. (2014, February 10). TYPHERIX®: *Salmonella typhi* Vi capsular polysaccharide vaccine. *Product Monograph*.
- Sanofi Pasteur Limited. (2013, November 26). TYPHIM Vi®: *Salmonella typhi* Vi capsular polysaccharide vaccine. *Product Monograph*.
- <sup>2</sup> National Advisory Committee on Immunization. (2012). *Canadian Immunization Guide* (Evergreen ed.). Ottawa, ON: Public Health Agency of Canada. [www.canada.ca/en/public-health/services/canadian-immunization-guide.html](http://www.canada.ca/en/public-health/services/canadian-immunization-guide.html)
- <sup>3</sup> Alberta Health. Typhoid. In *Public Health Notifiable Disease Management Guidelines*. [www.health.alberta.ca/professionals/notifiable-diseases-guide.html](http://www.health.alberta.ca/professionals/notifiable-diseases-guide.html)
- <sup>4</sup> Alberta Health. (2016, December). *Adverse Events Following Immunization (AEFI), Policy for Alberta Immunization Providers*. [www.health.alberta.ca/documents/AIP-Adverse-Events-Following-Immunization-Policy.pdf](http://www.health.alberta.ca/documents/AIP-Adverse-Events-Following-Immunization-Policy.pdf)